Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo - PubMed (original) (raw)
Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo
Snehal U Naik et al. Circulation. 2006.
Abstract
Background: Liver X receptors (LXRs) are ligand-activated transcription factors involved in the control of lipid metabolism and inflammation. Synthetic LXR agonists have been shown to inhibit the progression of atherosclerosis in mice, but the mechanism is uncertain. LXR agonism upregulates the genes encoding ATP binding cassette transporters A1 (ABCA1) and G1 (ABCG1) in macrophages, thus promoting efflux of cholesterol; it also upregulates liver and intestinal ABCG5 and ABCG8, helping to promote biliary and fecal excretion of cholesterol. Thus, LXR agonism may inhibit atherosclerosis through promotion of reverse cholesterol transport (RCT) in vivo, but this has not been proven. We previously described an in vivo method to trace the movement of cholesterol from 3H-cholesterol-labeled J774 macrophages into plasma, into liver, and ultimately into the bile and feces as free cholesterol or bile acids. In the present study we used this approach to test the hypothesis that administration of the synthetic LXR agonist GW3965 would increase the rate of macrophage RCT in vivo.
Methods and results: Three different mouse models-wild-type C57BL/6 mice, LDLR/apobec-1 double knockout mice, and human apolipoprotein (apo)B/cholesteryl ester transfer protein (CETP) double transgenic mice-were treated with either vehicle or GW3965. Mice were injected intraperitoneally with 3H-cholesterol-labeled and cholesterol-loaded macrophages and monitored for the appearance of 3H-tracer in plasma, liver, and feces. Administration of GW3965 significantly increased the levels of 3H-tracer in plasma and feces in all 3 mouse models.
Conclusions: These results demonstrate that administration of the LXR agonist GW3965 increases the rate of RCT from macrophages to feces in vivo.
Comment in
- Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune?
Lee CH, Plutzky J. Lee CH, et al. Circulation. 2006 Jan 3;113(1):5-8. doi: 10.1161/CIRCULATIONAHA.105.590273. Circulation. 2006. PMID: 16391165 Review. No abstract available.
Similar articles
- Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, Westerterp M. Kappus MS, et al. Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):279-84. doi: 10.1161/ATVBAHA.113.302781. Epub 2013 Dec 5. Arterioscler Thromb Vasc Biol. 2014. PMID: 24311381 Free PMC article. - Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.
Briand F, Tréguier M, André A, Grillot D, Issandou M, Ouguerram K, Sulpice T. Briand F, et al. J Lipid Res. 2010 Apr;51(4):763-70. doi: 10.1194/jlr.M001552. Epub 2009 Oct 27. J Lipid Res. 2010. PMID: 19965597 Free PMC article. - Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo.
Yasuda T, Grillot D, Billheimer JT, Briand F, Delerive P, Huet S, Rader DJ. Yasuda T, et al. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):781-6. doi: 10.1161/ATVBAHA.109.195693. Epub 2010 Jan 28. Arterioscler Thromb Vasc Biol. 2010. PMID: 20110577 Free PMC article. - Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism.
Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Wójcicka G, et al. Postepy Hig Med Dosw (Online). 2007 Dec 3;61:736-59. Postepy Hig Med Dosw (Online). 2007. PMID: 18063918 Review. - Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
Bełtowski J. Bełtowski J. Cardiovasc Ther. 2008 Winter;26(4):297-316. doi: 10.1111/j.1755-5922.2008.00062.x. Cardiovasc Ther. 2008. PMID: 19035881 Review.
Cited by
- Vulnerable plaque: from bench to bedside; local pacification versus systemic therapy.
Kasim S, Moran D, McFadden E. Kasim S, et al. Heart Views. 2012 Oct;13(4):139-45. doi: 10.4103/1995-705X.105731. Heart Views. 2012. PMID: 23439781 Free PMC article. - Liver X receptors, atherosclerosis and inflammation.
Michael DR, Ashlin TG, Buckley ML, Ramji DP. Michael DR, et al. Curr Atheroscler Rep. 2012 Jun;14(3):284-93. doi: 10.1007/s11883-012-0239-y. Curr Atheroscler Rep. 2012. PMID: 22419222 Review. - Immune cell screening of a nanoparticle library improves atherosclerosis therapy.
Tang J, Baxter S, Menon A, Alaarg A, Sanchez-Gaytan BL, Fay F, Zhao Y, Ouimet M, Braza MS, Longo VA, Abdel-Atti D, Duivenvoorden R, Calcagno C, Storm G, Tsimikas S, Moore KJ, Swirski FK, Nahrendorf M, Fisher EA, Pérez-Medina C, Fayad ZA, Reiner T, Mulder WJ. Tang J, et al. Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6731-E6740. doi: 10.1073/pnas.1609629113. Epub 2016 Oct 17. Proc Natl Acad Sci U S A. 2016. PMID: 27791119 Free PMC article. - Genetic variations at ABCG5/G8 genes modulate plasma lipids concentrations in patients with familial hypercholesterolemia.
Garcia-Rios A, Perez-Martinez P, Fuentes F, Mata P, Lopez-Miranda J, Alonso R, Rodriguez F, Garcia-Olid A, Ruano J, Ordovas JM, Perez-Jimenez F. Garcia-Rios A, et al. Atherosclerosis. 2010 Jun;210(2):486-92. doi: 10.1016/j.atherosclerosis.2010.01.010. Epub 2010 Jan 22. Atherosclerosis. 2010. PMID: 20172523 Free PMC article. - Molecular regulation of HDL metabolism and function: implications for novel therapies.
Rader DJ. Rader DJ. J Clin Invest. 2006 Dec;116(12):3090-100. doi: 10.1172/JCI30163. J Clin Invest. 2006. PMID: 17143322 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases